港股異動 | 康寧傑瑞製藥-B漲超6% 新藥臨牀試驗申請獲批准
格隆匯11月25日丨康寧傑瑞製藥-B(9966.HK)漲6.42%,報19.9港元,總市值186億港元。
公司KN046治療晚期PDAC的III期臨牀試驗日前獲國家藥監局IND批准,KN046-303是一項對未接受系統性治療的不可切除局部晚期或轉移性PDAC患者進行的,公司相信KN046有潛力被開發為突破性腫瘤免疫特效藥。據悉,集團已發佈KN046在治療既往免疫檢查點抑制劑治療失敗患者的初步及良好安全性和療效數據。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.